Etop Ibcsg Partners Foundation

This study tests a drug called tarlatamab in 48 people with advanced small cell lung cancer who have already tried one standard treatment. Participants receive tarlatamab through an IV until their cancer worsens or side effects become too severe. The main goal is to see how many …

This phase 3 trial tests whether the immunotherapy drug cemiplimab can prevent non-small cell lung cancer from returning after surgery. About 390 people with stage II-IIIA lung cancer who have not had chemotherapy will receive cemiplimab or be observed. The study focuses on patie…

This study looks at whether adding a precise type of radiation (stereotactic radiosurgery) to standard drug therapy can better control brain tumors in people with melanoma or non-small cell lung cancer that has spread to the brain. About 180 participants with newly diagnosed, unt…

This study tests whether giving the immunotherapy drug durvalumab after chemotherapy and surgery can help prevent lung cancer from coming back. About 290 adults with stage IIB-IIIB non-small cell lung cancer will receive durvalumab plus chemo before surgery, then either more durv…

This study tests whether adding the drug niraparib to standard immunotherapy can help keep extensive-stage small cell lung cancer from progressing. It is for people whose tumors have a specific marker called SLFN11 and who have not worsened after initial treatment. About 44 parti…